30-Second Takeaway
- About one-third of severe T2-high asthma patients reached 12‑month remission on first biologic; lower baseline CRP predicted success.
- All three approved CRSwNP biologics provided substantial real-world benefit, with highest 6‑month continuation on dupilumab.
- Anti–IL‑5 monoclonal antibodies safely improved CRSwNP symptoms and reduced systemic steroid and surgery needs as second-line therapy.
- Early upper-airway symptoms, otitis, and atopic heredity flagged young adults who later developed chronic rhinosinusitis.
- Air pollution particles and high-fructose beverages appear to amplify pediatric atopy and allergic airway inflammation through epithelial and myeloid pathways.
Week ending April 18, 2026
Type 2 airway disease: biologic remission, upper-airway control, and early-life and environmental modifiers
One-third of severe T2-high asthma patients achieved 12‑month remission; low CRP independently predicted success
In this retrospective single-center cohort, 206 severe T2-high asthma patients started their first biologic (omalizumab, mepolizumab, or benralizumab). At 12 months, 30% met strict clinical remission criteria: no exacerbations, no chronic oral steroids, and well-controlled symptoms on ACT and ACQ-6. Remission rates were similar across biologics, with numerically highest rates for benralizumab. Remitters had better baseline lung function, earlier disease onset, less smoking, and lower CRP, but only CRP remained predictive in multivariable analysis.
All three biologics improved severe CRSwNP in real life; dupilumab showed numerically highest continuation
This Belgian prospective multicentre phase IV cohort followed 360 severe CRSwNP patients starting omalizumab, mepolizumab, or dupilumab. After 6 months, nasal polyp scores, smell, and patient-reported outcomes improved across all treatments, alongside better asthma control. Overall, 51% achieved a good-to-excellent multidomain response by EUFOREA criteria, and no severe adverse events occurred. Treatment continuation beyond 6 months was 74% for omalizumab, 81% for mepolizumab, and 92% for dupilumab, with numerically larger improvements on dupilumab.
First-trimester PM2.5 components increased offspring atopic dermatitis risk, partly via maternal low-grade inflammation
Two prospective Chongqing birth cohorts contributed 4048 mother–child pairs with physician-diagnosed atopic dermatitis up to age 3. First-trimester exposure showed the strongest associations, with sulfate demonstrating the largest adjusted risk increase among PM2.5 components. Mixture modeling supported a positive association of combined components, with organic matter receiving the highest weight. Maternal neutrophil-to-lymphocyte ratio and systemic immune-inflammation index were associated with exposure, partially mediating risk and modifying effects on an additive scale.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.